title: Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
abstract: BACKGROUND
  Protocadherin17 (PCDH17) is a tumor suppressor gene, and is frequently silenced by promoter methylation in human cancers, including clear cell renal cell carcinoma (ccRCC). However, the clinical significance of PCDH17 methylation in ccRCC remains largely unclear. The aim of the present study was to investigate the methylation status of PCDH17 in ccRCC and its potential relevance to clinicopathological parameters and prognosis.
  
  
  METHODS
  Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. Subsequently, the associations between PCDH17 methylation and clinicopathological parameters and prognosis of patients with ccRCC were analyzed.
  
  
  RESULTS
  PCDH17 methylation occurred in 66.5% of ccRCC tumors, but in only 12.1% of adjacent noncancerous tissues. PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. Moreover, it is an independent prognostic factor for progression-free survival and overall survival of patients with ccRCC.
  
  
  CONCLUSIONS
  PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. Thus, PCDH17 methylation may be used as a novel biomarker to predict the prognosis of patients with ccRCC.
authors.affiliation: Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China (mainland).
authors.forename: Ying-Li
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Department of Urology, First Hospital of Jiamusi University, Jiamusi, Heilongjiang, China (mainland).
authors.forename: Shi-Liang
authors.initials: SL
authors.lastname: Gui
authors.affiliation: Department of Pharmacy, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Hong
authors.initials: H
authors.lastname: Guo
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Ma
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Wen-Ping
authors.initials: WP
authors.lastname: Li
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D015820:Cadherins / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000378:metabolism; D018899:CpG Islands; D019175:DNA Methylation; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011401:Promoter Regions, Genetic; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; C529349:PCDH17 protein, human